Barclays Maintains Overweight on Claritev, Raises Price Target to $40
Barclays analyst Glen Santangelo maintains Claritev (NYSE:CTEV) with a Overweight and raises the price target from $28 to $40.
Read original at benzingaStocks · News reference
Claritev Analysts Raise Their Forecasts Following Q2 Earnings
CTEV reported better-than-expected Q2 results and raised FY26 sales guidance. Analysts maintain Buy ratings with increased price targets.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 2:45 PM
- Checked
- Aug 10, 2026, 2:45 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans
Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX:MRAI) has expanded its relationship with Claritev to bring comprehensive pre- and
Read original at benzingaWells Fargo Maintains Equal-Weight on Claritev, Raises Price Target to $30
Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and raises the price target from $22 to $30.
Read original at benzinga